한글목차

랄로트렉티닙의 성장을 촉진하는 주요 요인들

1. 시장 점유율 확대 및 신규 환자 수 증가

• 랄로트렉티닙은 NTRK 유전자 융합에 대한 최초의 조직 비의존적 표적치료제로서 TRK 융합 양성 고형암 시장을 선도하고 있습니다.
• 종양학 분야에서의 종합적인 유전체 프로파일링(CGP)의 도입 확대는 적격 환자를 식별하고, 모든 종양 유형에서 새로운 치료 시작을 촉진하는 데 기여하고 있습니다.
• 바이엘과 파트너사인 Roche/Genentech가 종양 전문의와 병리학자를 위한 세계 교육 구상을 통해 바이오마커 검사 및 약물 도입을 가속화하고 있습니다.

2. 주요 적응증 확대

• NTRK 융합 양성 고형암(모든 조직형) : 랄로트렉티닙은 종양 발생 부위에 관계없이 성인 및 소아 환자군에서 승인되었습니다.
• 소아종양: NTRK 융합을 가진 희귀 소아종양에서 높은 반응률과 우수한 안전성을 바탕으로 강력한 사용 실적을 보유하고 있습니다.
• 조기 치료 라인: 신속하고 지속적인 반응으로 치료 초기 단계의 실제 임상에서 채택이 확대되고 있습니다.
• 파이프라인의 바이오마커 확대: 내성 돌연변이 및 차세대 TRK 억제제에 대한 연구가 진행 중이며, 향후 수명주기관리를 지원할 수 있습니다.

3. 지역적 확장

• 라로트렉티닙은 미국, EU, 일본 및 여러 세계 시장에서 승인되었습니다.
• 아시아태평양은 정밀 암 치료 프로그램의 확대와 각국의 게놈 검사 구상에 따라 높은 성장이 기대되는 지역입니다.
• 진단 기업과의 전략적 제휴를 통해 NTRK 검사에 대한 전 세계 접근성이 향상되고 있습니다.

4. 신규 적응증 승인

• 규제 당국은 NTRK 융합 양성 암에 대해 조직 비의존적 승인을 부여했습니다. 이는 정밀종양 분야에서 획기적인 사건입니다.
• 소아 적응증 확대 및 지역 간 표시 통일로 치료 대상 환자층이 확대되었습니다.
• 현재 진행 중인 실제 데이터와 규제 당국과의 대화를 통해 더 빠른 치료 라인에 위치할 수 있는 가능성을 시사하고 있습니다.

5. 정밀 종양 분야에서 강력한 사례 수 확대

• 정밀 종양 분야는 주요 촉진요인이며, TRK 융합 유전자 검사는 많은 종양 유형에서 표준화가 진행되고 있습니다.
• 높은 전체 반응률, 지속적인 질병 조절, 우수한 내약성으로 지속적인 처방량 증가를 지원하고 있습니다.
• 다양한 종양 유형에 대한 임상시험 결과가 실제 데이터로 지원되고 있습니다.

6. 경쟁 차별화 및 시장 동향

• 고선택적 TRK 저해는 다중 키나아제 억제제 대비 오프타겟 독성을 최소화합니다.
• 경구 표적 치료로 외래 치료가 가능해져 삶의 질이 향상됩니다.
• 바이오마커 기반 종양, 종양 독립적 승인, 정밀의료의 광범위한 추세는 랄로트렉티닙의 포지셔닝을 강력하게 지지하고 있습니다.
• 실제 데이터에 대한 의존도가 높아짐에 따라 지불자와 임상의의 신뢰성이 강화되고 있습니다.

이 보고서는 주요 7개 국가(미국, EU4(독일, 프랑스, 이탈리아, 스페인), 영국)에서 고형암과 같은 승인된 적응증과 조직구증, 비호지킨림프종, 중추신경계암과 같은 잠재적 적응증에 대한 종합적인 인사이트을 제공합니다. 2020-2034년까지 주요 7개국에서 라로트렉티닙의 승인된 적응증 및 잠재적 적응증에 대한 사용 현황, 진입 전망, 성과 전망, 승인된 적응증 및 잠재적 적응증에 대한 라로트렉티닙에 대한 자세한 설명과 함께 2020-2034년까지 주요 7개국에서 라로트렉티닙의 승인된 적응증 및 잠재적 적응증에 대한 자세한 설명을 제공합니다. 또한 이 약물의 매출 예측, 작용기전(MoA), 용량 및 투여방법, 규제 마일스톤을 포함한 연구개발 및 기타 활동에 대한 정보를 제공합니다. 또한 과거 및 현재 랄로트렉티닙의 실적, 미래 시장 평가, SWOT 분석, 애널리스트의 견해, 경쟁사 개요, 각 적응증별 다른 신흥 치료제의 개요, 매출 예측 분석, 시장 견인 요인 등을 정리했습니다.

목차

제1장 리포트 개요

제2장 라로트렉티닙 개요 : 고형 종양 등의 승인 적응증·조직구증, 비호지킨림프종, 중추신경계 암 등의 잠재적 적응증

제3장 라로트렉티닙 : 경쟁 구도(출시 치료제)

제4장 경쟁 구도 : 경쟁 구도(개발 후기 치료제)

제5장 라로트렉티닙 : 시장 평가

제6장 라로트렉티닙 : SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

Key Factors Driving Larotrectinib Growth

1. Market Share Gains and New Patient Starts

• Larotrectinib continues to lead the TRK fusion-positive solid tumor market as the first tissue-agnostic targeted therapy for NTRK gene fusions.
• Rising adoption of comprehensive genomic profiling (CGP) in oncology is expanding identification of eligible patients and driving new treatment starts across tumor types.
• Bayer and partner Roche/Genentech's global education initiatives for oncologists and pathologists are accelerating biomarker testing and drug uptake.

2. Expansion Across Key Indications

• NTRK Fusion-Positive Solid Tumors (All Histologies): Larotrectinib is approved across adult and pediatric populations regardless of tumor origin.
• Pediatric Oncology: Strong use in rare pediatric tumors with NTRK fusions, supported by high response rates and favorable safety.
• Earlier-Line Therapy: Growing real-world adoption in earlier lines of treatment due to rapid and durable responses.
• Pipeline Biomarker Expansion: Ongoing research into resistance mutations and next-generation TRK inhibitors supports future lifecycle management.

3. Geographic Expansion

• Larotrectinib is approved in the US, EU, Japan, and multiple global markets.
• Asia-Pacific is a high-growth region, driven by expanding precision oncology programs and national genomic testing initiatives.
• Strategic partnerships with diagnostic companies are improving global access to NTRK testing.

4. New Indication Approvals

• Regulatory agencies granted tissue-agnostic approval for NTRK fusion-positive cancers, a landmark in precision oncology.
• Expanded pediatric indications and label harmonization across regions have broadened the treatable population.
• Ongoing real-world data and regulatory interactions support potential earlier-line positioning.

5. Strong Precision Oncology Volume Momentum

• Precision oncology remains the key growth driver, with TRK fusion testing becoming standard in many tumor types.
• Sustained prescription growth is supported by high overall response rates, durable disease control, and favorable tolerability.
• Real-world evidence is confirming clinical trial outcomes across diverse tumor types.

6. Competitive Differentiation and Market Trends

• Highly selective TRK inhibition minimizes off-target toxicity compared with multi-kinase inhibitors.
• Oral targeted therapy enables outpatient treatment and improved quality of life.
• Broader trends toward biomarker-driven oncology, tumor-agnostic approvals, and precision medicine strongly support Larotrectinib's positioning.
• Growing reliance on real-world evidence (RWE) is strengthening payer and clinician confidence.

Larotrectinib Recent Developments

Bayer and Roche/Genentech have emphasized expanded global reimbursement, increased access to NTRK testing, and long-term follow-up data confirming durable responses in both adult and pediatric populations. New real-world studies presented at major oncology congresses continue to validate Larotrectinib's tissue-agnostic benefit and reinforce its role as the gold standard first-line TRK inhibitor for NTRK fusion-positive cancers.

"Larotrectinib Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Larotrectinib for approved indication like Solid tumours; as well as potential indications like Histiocytosis, Non-Hodgkin's lymphoma, and CNS Cancer in the 7MM. A detailed picture of Larotrectinib's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Larotrectinib for approved and potential indications. The Larotrectinib market report provides insights about Larotrectinib's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Larotrectinib performance, future market assessments inclusive of the Larotrectinib market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Larotrectinib sales forecasts, along with factors driving its market.

Larotrectinib Drug Summary

Larotrectinib (Vitrakvi) is a potent, selective, small-molecule tropomyosin receptor kinase (TRK) inhibitor targeting TRKA, TRKB, and TRKC kinases encoded by NTRK1, NTRK2, and NTRK3 genes, respectively, indicated for the treatment of adult and pediatric patients with solid tumors harboring NTRK gene fusions without known resistance mutations that are either metastatic or surgically unresectable with severe morbidity risk, and for whom no satisfactory prior treatments exist or disease has progressed. By competitively binding the ATP-binding pocket of aberrant TRK fusion proteins (e.g., ETV6-NTRK3, LMNA-NTRK1), it blocks constitutive downstream signaling via MAPK, PI3K, and PLCY pathways that drive oncogenesis, resulting in rapid, durable tumor responses across NTRK fusion-positive cancers like salivary gland tumors, infantile fibrosarcoma, and lung/thyroid/colorectal adenocarcinomas independent of histology (objective response rate ~75% in trials). Administered orally as capsules (100 mg BID) or oral solution (10 mg/mL) continuously in 28-day cycles with dose modifications for toxicities like elevated ALT/AST, anemia, weight loss, and neutropenia, larotrectinib requires confirmed NTRK fusion via molecular testing (NGS/PCR/FISH/IHC) prior to initiation. The report provides Larotrectinib's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Larotrectinib Market Report

The report provides insights into:

• A comprehensive product overview including the Larotrectinib MoA, description, dosage and administration, research and development activities in approved indications like Solid tumours; as well as potential indications like Histiocytosis, Non-Hodgkin's lymphoma, and CNS Cancer.
• Elaborated details on Larotrectinib regulatory milestones and other development activities have been provided in Larotrectinib market report.
• The report also highlights Larotrectinib's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Larotrectinib market report also covers the patents information, generic entry and impact on cost cut.
• The Larotrectinib market report contains current and forecasted Larotrectinib sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Larotrectinib market report also features the SWOT analysis with analyst views for Larotrectinib in approved and potential indications.

Methodology:

The Larotrectinib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Larotrectinib Analytical Perspective by DelveInsight

• In-depth Larotrectinib Market Assessment

This Larotrectinib sales market forecast report provides a detailed market assessment of Larotrectinib for approved indication like Solid tumours; as well as potential indications like Histiocytosis, Non-Hodgkin's lymphoma, and CNS Cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Larotrectinib sales data uptil 2034.

• Larotrectinib Clinical Assessment

The Larotrectinib market report provides the clinical trials information of Larotrectinib for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Larotrectinib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Larotrectinib Market Potential & Revenue Forecast

• Projected market size for the Larotrectinib and its key indications
• Estimated Larotrectinib sales potential (Larotrectinib peak sales forecasts)
• Larotrectinib Pricing strategies and reimbursement landscape

Larotrectinib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Larotrectinib Market positioning compared to existing treatments
• Larotrectinib Strengths & weaknesses relative to competitors

Larotrectinib Regulatory & Commercial Milestones

• Larotrectinib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Larotrectinib Clinical Differentiation

• Larotrectinib Efficacy & safety advantages over existing drugs
• Larotrectinib Unique selling points

Larotrectinib Market Report Highlights

• In the coming years, the Larotrectinib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Larotrectinib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Larotrectinib's dominance.
• Other emerging products for Solid tumours; as well as potential indications like Histiocytosis, Non-Hodgkin's lymphoma, and CNS Cancer are expected to give tough market competition to Larotrectinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Larotrectinib in approved and potential indications.
• Analyse Larotrectinib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Larotrectinib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Larotrectinib in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Larotrectinib? How strong is Larotrectinib's clinical and commercial performance?
• What is Larotrectinib's clinical trial status in each individual indications such as Solid tumours; as well as potential indications like Histiocytosis, Non-Hodgkin's lymphoma, and CNS Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Larotrectinib Manufacturers?
• What are the key designations that have been granted to Larotrectinib for approved and potential indications? How are they going to impact Larotrectinib's penetration in various geographies?
• What is the current and forecasted Larotrectinib market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Larotrectinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Larotrectinib for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Larotrectinib? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Larotrectinib Overview in approved indications like Solid tumours; as well as potential indications like Histiocytosis, Non-Hodgkin's lymphoma, and CNS Cancer

• 2.1. Product Detail
• 2.2. Larotrectinib Clinical Development
  • 2.2.1. Larotrectinib Clinical studies
  • 2.2.2. Larotrectinib Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Larotrectinib Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Larotrectinib Therapies)

5. Larotrectinib Market Assessment

• 5.1. Larotrectinib Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Larotrectinib Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Larotrectinib Market Size in the United States for approved and potential indications
  • 5.3.2. Larotrectinib Market Size in Germany for approved and potential indications
  • 5.3.3. Larotrectinib Market Size in France for approved and potential indications
  • 5.3.4. Larotrectinib Market Size in Italy for approved and potential indications
  • 5.3.5. Larotrectinib Market Size in Spain for approved and potential indications
  • 5.3.6. Larotrectinib Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. Larotrectinib Market Size in Japan for approved and potential indications

6. Larotrectinib SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options